SK Bioscience (302440) stock
KOSPI · Pharmaceuticals
As of Nov 16, 2:35 PM KST
Events and reference metrics · 1
- Market cap
- KRW 3.1 trillion
- As of Nov 16, 2026
- P/E
- -31.08x
- Trailing twelve months
- P/B
- 1.73x
- Latest reported equity
- P/S
- 4.44x
- Trailing twelve months
- ROE
- -5.6%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 16, 2026 and may differ from the current price.
- Market cap
- KRW 3.1 trillion
- As of Nov 16, 2026
- P/E
- -31.08x
- Trailing twelve months
- P/B
- 1.73x
- Latest reported equity
- P/S
- 4.44x
- Trailing twelve months
- ROE
- -5.6%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 16, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 16, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
-31.08x
Net loss — not comparable
P/B
1.73x
P/S
4.44x
Earnings and dividend metrics▾
Earnings
EPS
-KRW 1,257
Earnings per share
BPS
KRW 22,571
Book value per share
ROE
-5.6%
Return on equity
- EPS — what one share earned over the last four quarters. The company is currently loss-making, at KRW 1,257 per share.
- BPS — net assets divided by the number of shares. Each share is backed by KRW 22,571 of net assets.
- ROE — shareholder equity shrank by 5.6% over a year.
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from DART financial filings: net income attributable to owners of the parent and revenue are summed over the latest four quarters, equity is the latest reported equity, and prices are KRX closing prices.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Earnings
Revenue, operating profit and net income from periodic reports filed with DART, Korea’s regulatory filing system.
| Period | Revenue | Operating profit | Net income | Revenue YoY |
|---|---|---|---|---|
| Q2 2026Consolidated · Filed Aug 13, 2026 | KRW 155.7 billion | -KRW 15.7 billion | -KRW 14.1 billion | -3.8% |
| Q1 2026Consolidated · Filed May 13, 2026 | KRW 168.6 billion | -KRW 44.5 billion | -KRW 36.2 billion | +9.1% |
| Q4 2025Consolidated · Filed Mar 13, 2026 | KRW 184.2 billion | -KRW 51.6 billion | -KRW 56.4 billion | — |
| Q3 2025Consolidated · Filed Nov 13, 2025 | KRW 150.8 billion | -KRW 19.4 billion | KRW 21.1 billion | +144.6% |
| Q2 2025Consolidated · Filed Aug 12, 2025 | KRW 161.9 billion | -KRW 37.4 billion | -KRW 16.8 billion | +504.5% |
| Q1 2025Consolidated · Filed May 14, 2025 | KRW 154.6 billion | -KRW 15.1 billion | -KRW 4.1 billion | +594.0% |
| Period | Revenue | Operating profit | Net income | Revenue YoY |
|---|---|---|---|---|
| FY2025Consolidated · Filed Mar 13, 2026 | KRW 651.4 billion | -KRW 123.5 billion | -KRW 56.2 billion | +143.5% |
| FY2024Consolidated · Filed Mar 17, 2025 | KRW 267.5 billion | -KRW 138.4 billion | -KRW 50.1 billion | — |
- Q2 2026 is computed as H1 2026 minus Q1 2026.
- Q4 2025 is computed as FY2025 minus 9M 2025.
- Q3 2025 is computed as 9M 2025 minus H1 2025.
- Q2 2025 is computed as H1 2025 minus Q1 2025.
Short selling and securities lending
Short sales as a share of trading value, the reported short position and the securities lending balance.
- Short-sale share
- 4.67%
- Of trading value on Nov 13, 2026
- Short-sale value
- KRW 160 million
- Previous 20-day average 12.01%
- Net short position
- 760,750 shares
- As of Nov 11, 2026 · reported with a two-trading-day lag
- Lending balance
- 2,823,290 shares
- As of Nov 13, 2026 · 3.60% of listed shares
| Date | Share | Value |
|---|---|---|
| Nov 13, 2026 | 4.67% | KRW 160 million |
| Nov 12, 2026 | 13.90% | KRW 830 million |
| Nov 11, 2026 | 8.73% | KRW 520 million |
| Nov 10, 2026 | 14.39% | KRW 1.16 billion |
| Nov 9, 2026 | 6.54% | KRW 1.99 billion |
| Nov 6, 2026 | 2.34% | KRW 280 million |
| Nov 5, 2026 | 3.36% | KRW 260 million |
| Nov 4, 2026 | 5.78% | KRW 260 million |
| Nov 3, 2026 | 6.05% | KRW 390 million |
| Nov 2, 2026 | 10.64% | KRW 230 million |
The short-sale share is short-sale value divided by total trading value that day. The lending balance also includes stock lent for purposes other than short selling.
Filings
Major filings received by DART, Korea’s regulatory filing system.
- Preliminary Consolidated Operating Results (Fair Disclosure)Nov 5, 2026 · Preliminary EarningsEnglish
- Preliminary Consolidated Operating Results (Fair Disclosure)(Korean)Aug 10, 2026 · Preliminary Earnings
- Single Sales or Supply Contract(Korean)Jun 23, 2026 · Supply Contract
- Preliminary Consolidated Operating Results (Fair Disclosure)(Korean)May 6, 2026 · Preliminary Earnings
- Decision on Share Buyback(Korean)Apr 28, 2026 · Share Buyback
- Report on Major Holdings of Shares (General Form)(Korean)Mar 27, 2026 · Major Holding Report
- Report on Specified Securities Held by Executives and Major Shareholders(Korean)Mar 26, 2026 · Insider Ownership Report
- Report on Changes in Shares Held by the Largest Shareholder and Related Parties(Korean)Mar 25, 2026 · Largest Shareholder Holding Change
Filings with a published English version open in English; the rest link to the Korean original.
SK Bioscience (302440) stock information
KOSPI
SK Bioscience (302440) is listed on KOSPI. Its market capitalization is about KRW 3.1 trillion. On trailing-twelve-month earnings the P/E ratio is -31.08, and the P/B ratio is 1.73. Return on equity is -5.6%. These figures are computed in-house from official filings and are reference information only.
SK Bioscience — frequently asked questions
- What is the P/E ratio of SK Bioscience (302440)?
- On a trailing-twelve-month basis, 302440 trades at a P/E ratio of -31.08. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of SK Bioscience?
- 302440 has a market capitalization of about KRW 3.1 trillion. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.